1jq7: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==HCMV protease dimer-interface mutant, S225Y complexed to Inhibitor BILC 408== | ==HCMV protease dimer-interface mutant, S225Y complexed to Inhibitor BILC 408== | ||
<StructureSection load='1jq7' size='340' side='right' caption='[[1jq7]], [[Resolution|resolution]] 3.00Å' scene=''> | <StructureSection load='1jq7' size='340' side='right'caption='[[1jq7]], [[Resolution|resolution]] 3.00Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[1jq7]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Hcmv Hcmv]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1JQ7 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1JQ7 FirstGlance]. <br> | <table><tr><td colspan='2'>[[1jq7]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Hcmv Hcmv]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1JQ7 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1JQ7 FirstGlance]. <br> | ||
Line 30: | Line 30: | ||
</div> | </div> | ||
<div class="pdbe-citations 1jq7" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 1jq7" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Virus protease|Virus protease]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
Line 36: | Line 39: | ||
[[Category: Assemblin]] | [[Category: Assemblin]] | ||
[[Category: Hcmv]] | [[Category: Hcmv]] | ||
[[Category: Large Structures]] | |||
[[Category: Batra, R]] | [[Category: Batra, R]] | ||
[[Category: Khayat, R]] | [[Category: Khayat, R]] |
Revision as of 12:42, 6 November 2019
HCMV protease dimer-interface mutant, S225Y complexed to Inhibitor BILC 408HCMV protease dimer-interface mutant, S225Y complexed to Inhibitor BILC 408
Structural highlights
Function[SCAF_HCMVA] Capsid scaffolding protein acts as a scaffold protein by binding major capsid protein UL86 in the cytoplasm, inducing the nuclear localization of both proteins. Multimerizes in the nucleus such as protein UL86 forms the icosahedral T=16 capsid. Autocatalytic cleavage releases the assembly protein, and subsequently abolishes interaction with major capsid protein UL86. Cleavages products are evicted from the capsid before or during DNA packaging (By similarity). Assemblin is a protease essential for virion assembly in the nucleus. Catalyzes the cleavage of the assembly protein after complete capsid formation. Assemblin and cleavages products are evicted from the capsid before or during DNA packaging (By similarity). Assembly protein plays a major role in capsid assembly. Acts as a scaffold protein by binding major capsid protein UL86. Multimerizes in the nucleus such as protein UL86 forms the icosahedral T=16 capsid. Cleaved by assemblin after capsid completion. The cleavages products are evicted from the capsid before or during DNA packaging (By similarity). Evolutionary Conservation![]() Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedBiochemical studies indicate that dimerization is required for the catalytic activity of herpesvirus proteases, whereas structural studies show a complete active site in each monomer, away from the dimer interface. Here we report kinetic, biophysical and crystallographic characterizations of structure-based mutants in the dimer interface of human cytomegalovirus (HCMV) protease. Such mutations can produce a 1,700-fold reduction in the kcat while having minimal effects on the K(m). Dimer stability is not affected by these mutations, suggesting that dimerization itself is insufficient for activity. There are large changes in monomer conformation and dimer organization of the apo S225Y mutant enzyme. However, binding of an activated peptidomimetic inhibitor induced a conformation remarkably similar to the wild type protease. Our studies suggest that appropriate dimer formation may be required to indirectly stabilize the protease oxyanion hole, revealing a novel mechanism for dimerization to regulate enzyme activity. Molecular mechanism for dimerization to regulate the catalytic activity of human cytomegalovirus protease.,Batra R, Khayat R, Tong L Nat Struct Biol. 2001 Sep;8(9):810-7. PMID:11524687[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|